Related Experiment Video
Updated: Jul 16, 2026
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
Establishing multiple cost-effectiveness thresholds in Oman: a stakeholder-driven approach
Said Wani1,2,3, Hilal Alsabti4, Said Allamki4
1Center for Health Technology Assessment, Semmelweis University, Ulloi ut 25, Budapest, 1085, Hungary. said.rashdi@phd.semmelweis.hu.
Background:
The rising cost of new health technologies and limited healthcare budgets challenge health systems worldwide, including Oman. Local value judgments are crucial for informed decision-making. This study aims to establish a cost-effectiveness thresholds (CETs) framework for Oman, aligned with the country's economic status and healthcare priorities.
Methods:
The key findings from a recent literature review on global CETs and their applications were shared and discussed during a multi-stakeholder workshop in March 2024. Presenting these findings has provided participants a broad understanding of global CET practices and highlighted the use of multiple thresholds across different settings. Afterwards, a survey was distributed, asking participants to anonymously vote on six key concepts: the basis for the threshold, the baseline threshold multiplier, the use of multiple thresholds, the criteria for multiple thresholds, the number of multipliers, and which criterion should receive the 3X multiplier. The results from this voting guided the design and final agreement on the threshold values.
Results:
Twenty respondents supported adopting multiple CET values based on cost per quality-adjusted life-year (QALY), linked to Oman's economic status. A baseline CET equal to 1x Gross Domestic Product (GDP) per capita was suggested. Participants recommended three different threshold multipliers to reflect policy priorities. A continuous multiplier (1-3x GDP), based on incremental QALY gains, was used to favor technologies with greater health gains. Additionally, a fixed multiplier of 2 was chosen for both orphan drugs and treatments for priority diseases. The resulting CET values reflect technical and expert consensus and do not include patient or public perspectives.
Conclusions:
In Oman, the incremental cost per QALY gained should not exceed 1x GDP per capita for new health technologies that offer minimal health gains in common diseases. However, thresholds might increase to 12x GDP per capita for curative treatments in rare priority disease areas. It is recommended that CET values be reviewed and updated within three years, based on initial implementation experiences.
Related Concept Videos
01:09Decision Making: P-value Method
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:26Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
01:28Methods of Medium Optimization
01:01Production Efficiency
01:26Methods of Documentation II: POMR